Evofem Biosciences EVFM
OTC EVFM
$0.01 +0.00 (+0.00%)
As of: Oct 23, 2026 · 9:49 AM EDT

Evofem Biosciences (EVFM) Asset Writedowns and Impairment (2021 - 2025)

Updated

Evofem Biosciences (EVFM) recorded Asset Writedowns and Impairment of $178,000 in Q1 2025.

Analysis

Evofem Biosciences (EVFM) Asset Writedowns and Impairment (2021 - 2025) Analysis & Trends

On a TTM basis, Evofem Biosciences' Asset Writedowns and Impairment came in at -$677,000 as of Mar 31, 2025; for FY2024, it came in at $63,000, down 96.0% from FY2023.

  • Annual Asset Writedowns and Impairment has a three-year compound annual growth rate of -40.6% (FY2021 to FY2024).
  • Across earlier years, Asset Writedowns and Impairment came in at $1.58 million in FY2023, -$300,000 in FY2022 and $300,000 in FY2021.
  • The Q1 2025 figure is the highest quarterly Asset Writedowns and Impairment since Q4 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn
10 Evofem Biosciences 878,961.72 878,961.72 2.12 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 178,000.00
Dec 31, 2023 71,000.00
Dec 31, 2022 -1.23 Mn
Dec 31, 2021 300,000.00
API Access

Evofem Biosciences Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=EVFM&period=max&api_key=YOUR_API_KEY